Table 4.
Neoadjuvant bevacizumab trials in HER2-negative breast cancer
| Trial (definition of pCR) | pCR | DFS | OS | ||
|---|---|---|---|---|---|
| All (%) | ER/PgR positive (%) | ER and PgR negative (%) | |||
| S0800 (ypT0, ypTis, ypN0) | 3 years | 3 years | |||
| Bevacizumab | 36 | 24 | 59 | HR = 0.89 P = 0.71 |
86 % |
| No bevacizumab | 21 | 18 | 29 | 87 % | |
| GeparQuinto [41] (ypT0, ypN0) | 3 years | 3 years | |||
| Bevacizumab | 18.4 | 7.7 | 39.9 | 80.8 % | 90.7 % |
| No bevacizumab | 14.9 | 7.8 | 81.5 | 81.5 % | 88.7 % |
| Artemis [40] (ypT0, ypTis, ypN0) | Not reported | Not reported | |||
| Bevacizumab | 22.0 | 6.0 | 45.0 | ||
| No bevacizumab | 17.0 | 7.0 | 31.0 | ||
| NSABP-B40 [44] (ypT0, any pN) | 5 years | 5 years | |||
| Bevacizumab | 34.5 | 23.2 | 51.1 | HR = 0.8 P = 0.06 |
HR = 0.65 P = 0.004 |
| No bevacizumab | 28.2 | 15.1 | 47.1 | ||
| CALGB 40603 [43] (ypT0, any pN) | Not reported | Not reported | |||
| Bevacizumab | NA | NA | 59 | ||
| No Bevacizumab | NA | NA | 48 | ||
ER estrogen receptor, HR hazard ratio, pCR pathologic complete response, PGR progesterone receptor, TN triple negative, DFS disease-free survival, OS overall survival, NA not applicable